[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Mind Medicine (MindMed) Inc. (MNMD) has filed a Form 144, signaling the planned sale of 26,491 common shares. The shares—acquired on 06/25/2025 through the vesting of restricted stock granted under a company plan—are to be sold through Morgan Stanley Smith Barney LLC. Based on an aggregate market value of $180,210.33, the filing values the shares at roughly $6.80 each.

The proposed sale represents a de-minimis 0.035 % of the company’s 75,553,266 shares outstanding and is scheduled to occur on or after 06/25/2025 on the NASDAQ. No additional share sales by the same party were reported for the past three months, and no material adverse information is claimed by the seller in accordance with Rule 144 representations.

Because Form 144 filings merely notify the market of an intent to sell and do not guarantee execution, the practical impact is usually limited unless the size is significant or the seller is a key insider. Given the relatively small volume and lack of prior sales, this notice appears routine and unlikely to materially affect MNMD’s float or share-price dynamics.

Insights

Securities Analyst

TL;DR: Routine Form 144 for 26.5k shares (~$180k); negligible 0.035 % of float—limited market impact expected.

The filing alerts investors that an affiliate intends to dispose of 26,491 MNMD shares. With outstanding shares exceeding 75 million, dilution or float pressure is immaterial. The sale is tied to a restricted-stock vesting event—common for employee compensation. No clustered insider selling or negative disclosures accompany the notice, and no prior 3-month sales were reported. Overall, the transaction looks like standard liquidity management rather than a bearish signal.

Corporate Governance Expert

TL;DR: Insider liquidity event via registered plan; governance implications minimal, transparency intact.

Form 144 filings ensure compliance with Rule 144 resale restrictions. The seller affirms no undisclosed adverse information. The modest size, together with timely disclosure and use of a major brokerage, points to good governance practice. Investors should monitor cumulative insider activity, but this single, small sale does not raise red flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tessari Eben

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	06/16/2025		M(1)		6,500	A	$8.83	78,863	D
Class A Ordinary Share	06/16/2025		S(1)		17,300	D	$28.28(2)	61,563	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$8.83	06/16/2025		M(1)			6,500	(3)	09/16/2029	Class A Ordinary Share	6,500	$0	38,500	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.795 and $28.645. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Madelyn Zeylikman, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.